The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.

Borrower

P••••••• P••••••••• I••

Drug Discovery & Developmentgroup grade Aoff every schedule since Dec 31, 2023sponsor unattributed
See every lender's markFind rescue capital
More
Special situations PE firms

Nothing material in the last 200 days. Last change: 31 Dec 2023, $130M principal held by 1 lender; matures Dec 2027.

Principal held
at least $130M
sum of BDC pieces, a lower bound
Fair value
$128M
98c on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
1
0 equity pieces beside them
Next maturity
Dec 1, 2027
no dated debt inside 24 months
On the tape since
Dec 31, 2023
latest Dec 31, 2023
Events
2
dated, non-routine
Lender marks
each lender's own fair value over cost at Dec 31, 2023, folded to one row per lender
LenderExposureCurrent markQoQ change
H••••••• C••••••• I•••$130M98¢new this quarter
Every BDC piece · 1 position across 1 lenderlargest principal first, with instrument and rate
BDCInstrumentPrincipalFair valueRate
H••••••• C••••••• I•••term loan first lien
S••••• S••••••, M••••••• D••• D••••••• 2027, P•••• + 1.35%, F•••• rate 9.85%, PIK I•••••••
$130M$128M
98c
S+135 bp
PIK 2.15%
Capital structure as the BDCs see it
latest quarter end Dec 31, 2023
FacilityHeldOn costPricingMaturityBDCs
first lien term loan first lien
exited Dec 31, 2023
at least $130M98cS+135 bp
PIK 2.15%
Dec 1, 20271
Through time
the borrower's pieces summed across BDCs, every quarter end
Quarter endBDCsPrincipal heldFair valueOn costPIK pieces
Dec 31, 20231$130M$128M98c1
What changed
Every change including routine ones
Identity
Group key
P••••••• P•••••••••derivedthe codename stem after legal suffixes and deal words
Spellings
1 across 1 BDCderived
Industry
Drug Discovery & Developmentreportedas one filer wrote it